Skip to content

PP&E (Net) at other companies

Amgen logo
AmgenAMGN
$8.22B+23.0%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$3.2M-42.4%
Immunome logo
ImmunomeIMNM
$17.08M+55.9%
CG Oncology logo
CG OncologyCGON
$15.07M+5,610%
Erasca, Inc. logo
Erasca, Inc.ERAS
$12.61M-19.1%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$1.22M-76.3%

Segments

By geography

See full
United States$12.94M-0.9%
United Kingdom$909K+62.9%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's PP&E (net)?
Replimune Group (REPL) reported PP&E (net) of $13.85M in Q4 2025.
How has Replimune Group's PP&E (net) changed year-over-year?
Replimune Group's PP&E (net) increased by 1.7% year-over-year, from $13.62M to $13.85M.
What is the long-term trend for Replimune Group's PP&E (net)?
Over 4 years (2021 to 2025), Replimune Group's PP&E (net) has grown at a 16.6% compound annual growth rate (CAGR), from $7.44M to $13.74M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.